SK Biopharmaceuticals , Ltd. EBIT

SK Biopharmaceuticals , Ltd. (326030.KS) currently reports a EBIT of $220B as of June 2026. That compares with $220B in the prior-year period — up 1.4% year over year. That is above the Healthcare sector average of $99B. Use the charts on this page to explore SK Biopharmaceuticals , Ltd.'s EBIT history and peer comparisons.

SK Biopharmaceuticals , Ltd.'s EBIT increased from $220B to $220B — a 1.4% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

SK Biopharmaceuticals , Ltd.'s EBIT of $220B is higher than the Healthcare sector average of $99B. That is roughly 121.7% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

SK Biopharmaceuticals , Ltd. reported $220B in EBIT as of June 2026. That compares with $220B in the prior-year period — up 1.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $220B, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $99B. From there, open related valuation or income-statement pages for SK Biopharmaceuticals , Ltd., and consider following 326030.KS for alerts when major investors trade the stock.